Source: Polaris Market Research Analysis Key Players and Competitive Insights Novo Nordisk maintains a dominant position in the semaglutide market through its exclusive rights to develop, manufacture, and commercialize Ozempic, Wegovy, and Rybelsus
In addition to pain relief, semaglutide improved physical function, measured by the SF-36 Health Survey, with an average increase of 12 points, nearly doubling the improvement seen with placebo
In the end, it was an easy choice
For exact pricing details and current rates, its best to visit their pricing page on Edens website
Blacker KL et al
Healthcare professionals observe for any adverse reactions or complications, although they are rare